Stoke Therapeutics (STOK) Net Margin: 2022-2025
Historic Net Margin for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to -360.68%.
- Stoke Therapeutics' Net Margin rose 17937.00% to -360.68% in Q3 2025 from the same period last year, while for Sep 2025 it was 19.63%, marking a year-over-year increase of 64973.00%. This contributed to the annual value of -242.74% for FY2024, which is 95162.00% up from last year.
- Stoke Therapeutics' Net Margin amounted to -360.68% in Q3 2025, which was down 112.22% from -169.96% recorded in Q2 2025.
- Stoke Therapeutics' 5-year Net Margin high stood at 71.19% for Q1 2025, and its period low was -1,237.20% during Q2 2023.
- Over the past 3 years, Stoke Therapeutics' median Net Margin value was -531.88% (recorded in 2024), while the average stood at -507.86%.
- Per our database at Business Quant, Stoke Therapeutics' Net Margin crashed by 47,292bps in 2023 and then soared by 91,632bps in 2024.
- Quarterly analysis of 4 years shows Stoke Therapeutics' Net Margin stood at -786.32% in 2022, then slumped by 17,724bps to -963.56% in 2023, then surged by 91,632bps to -47.24% in 2024, then skyrocketed by 17,937bps to -360.68% in 2025.
- Its Net Margin stands at -360.68% for Q3 2025, versus -169.96% for Q2 2025 and 71.19% for Q1 2025.